

Clinical Trial Protocol

Iranian Registry of Clinical Trials

12 Jul 2026

Comparison of the effect of Hypericum perforatum Vaginal gel and Clotrimazole Vaginal cream on Vaginal Candida albicans infection: A double-blind randomized clinical trial

Protocol summary

Study aim

Determining and comparing the effects of Hypericum perforatum vaginal gel and clotrimazole vaginal cream on vaginal Candida albicans infection

Design

This is a randomized, double-blind, controlled clinical trial. which has a parallel group and will be performed on 80 patients with inclusion criteria. Random block method is used for randomization.

Settings and conduct

The research environment will be Shahid Mofateh Clinic in Yasuj city. The service provider screens the patients along with the gynecologist. For the final confirmation of the diagnosis, a serological test will be taken from the vaginal secretions. Only the pharmacist knows the type of drug used, and the researcher and service provider, the out come assessor and analyst, and the patient will be unaware of the type of drug used.

Participants/Inclusion and exclusion criteria

Inclusion criteria 1- Women of reproductive age (18-49)
2- Presence of cheesy vaginal discharge and doctor's confirmation 3- Complaints of burning, itching and swelling and pain in the vulva and vagina
Exclusion criteria: 1- Lactating women 2- Pregnant women 3- Women who smoke 4- The possibility of starting menstruation in the next 10 days 5- Having intercourse in the last 24 hours 6- Washing the vagina and using vaginal medicine in the last 48 hours 8- History of candida vaginitis

Intervention groups

The intervention group includes women who presented with complaints of candida vaginitis symptoms and after the final diagnosis through clinical symptoms and serological tests, Hypericum perforatum vaginal cream therapeutic intervention will be performed on them.

Main outcome variables

Itching, Burning, the pain, Inflammation, Cheesy

secretions

General information

Reason for update

Acronym

IRCT registration information

IRCT registration number: **IRCT20231017059753N1**

Registration date: **2023-12-20, 1402/09/29**

Registration timing: **registered_while_recruiting**

Last update: **2023-12-20, 1402/09/29**

Update count: **0**

Registration date

2023-12-20, 1402/09/29

Registrant information

Name

leila bozorgian

Name of organization / entity

Country

Iran (Islamic Republic of)

Phone

+98 74 3323 0240

Email address

liela.bozorgian1@gmail.com

Recruitment status

Recruitment complete

Funding source

Expected recruitment start date

2023-11-22, 1402/09/01

Expected recruitment end date

2024-02-19, 1402/11/30

Actual recruitment start date

empty

Actual recruitment end date

empty

Trial completion date

empty

Scientific title

Comparison of the effect of Hypericum perforatum Vaginal gel and Clotrimazole Vaginal cream on Vaginal Candida albicans infection: A double-blind randomized clinical trial

Public title

Comparison of the effect of Hypericum perforatum Vaginal gel and Clotrimazole Vaginal cream on Vaginal Candida albicans infection: A double-blind randomized clinical trial

Purpose

Treatment

Inclusion/Exclusion criteria**Inclusion criteria:**

1- Women of reproductive age (18-49)- 2- Presence of cheesy vaginal discharge and doctor's confirmation 3- Complaints of burning, itching and swelling and pain in the vulva and vagina 4- Absence of other vaginal infections 5- Willingness to participate in the study 6- Women with sexual partners

Exclusion criteria:

1- Lactating women 2- Pregnant women 3- Women who smoke 4- The possibility of starting menstruation in the next 10 days 5- Having abnormal vaginal bleeding at the time of sampling 6- Having intercourse in the last 24 hours 7- Washing the vagina and using vaginal medicine in the last 48 hours 8- Having a history of any type of transplantation and using immunosuppressive drugs and broad-spectrum antibiotics, hormonal drugs and combined contraceptive pills, anti prostaglandins and anticoagulant drugs in the last month, and antiepileptic and migraine drugs or women with Heart and kidney diseases or sexually transmitted diseases. 9- History of Candida infection in the last 6 months and its treatment 10- History of candidal vaginitis

Age

From **18 years** old to **49 years** old

Gender

Female

Phase

3

Groups that have been masked

- Participant
- Care provider
- Investigator
- Outcome assessor
- Data analyser

Sample size

Target sample size: **80**

Randomization (investigator's opinion)

Randomized

Randomization description

Sampling will be in the form of random block sampling based on the purpose and according to the study entry criteria. We consider the block size to be 5. Therefore, based on the sample size, we will have 20 blocks. When sampling starts, the first block will be randomly assigned

one of the codes A or B. Based on the received code of the first block, the second code will be sent to the second block, the first code will be sent to the third block, the second code will be sent to the fourth block, and so on until the end of the 20th block.

Blinding (investigator's opinion)

Double blinded

Blinding description

Hypericum perforatum vaginal gel and Clotrimazole vaginal cream have already been compared by the pharmacist in terms of appearance, color, size, smell and coded (A and B). The researcher, the service provider, the data analyst and the patient are unaware of the type of drug used, and only the pharmacist will be aware of this coding.

Placebo

Used

Assignment

Parallel

Other design features**Secondary Ids**

empty

Ethics committees**1****Ethics committee****Name of ethics committee**

Ethics Committee of Yasuj University of Medical Sciences

Street address

Shahid Motahari St., Yasouj University of Medical Sciences, Research Assistant

City

Yasuj

Province

Kohgiluyeh-va-Boyer-Ahmad

Postal code

7591994799

Approval date

2023-10-31, 1402/08/09

Ethics committee reference number

IR.YUMS.REC.1402.132

Health conditions studied**1****Description of health condition studied**

Candida vaginitis

ICD-10 code

N76.1

ICD-10 code description

Subacute and chronic vaginitis

Primary outcomes

1

Description

Itching

Timepoint

Results will be measured ten days to two weeks after the end of the treatment period.

Method of measurement

The way to measure the variable will be through a laboratory test and also a researcher-made questionnaire of clinical symptoms

2

Description

Burning

Timepoint

Results will be measured ten days to two weeks after the end of the treatment period.

Method of measurement

The way to measure the variable will be through a laboratory test and also a researcher-made questionnaire of clinical symptoms

3

Description

vaginal pain

Timepoint

Results will be measured ten days to two weeks after the end of the treatment period.

Method of measurement

The way to measure the variable will be through a laboratory test and also a researcher-made questionnaire of clinical symptoms.

4

Description

Inflammation

Timepoint

Results will be measured ten days to two weeks after the end of the treatment period.

Method of measurement

The way to measure the variable will be through a laboratory test and also a researcher-made questionnaire of clinical symptoms.

5

Description

Cheesy secretions

Timepoint

Results will be measured ten days to two weeks after the end of the treatment period.

Method of measurement

The way to measure the variable will be through a laboratory test and also a researcher-made questionnaire of clinical symptoms.

Secondary outcomes

1

Description

Satisfaction with treatment

Timepoint

One week to ten days after the intervention

Method of measurement

questionnaire

Intervention groups

1

Description

The intervention group will use the vaginal gel of gerbera prepared by the pharmacist with a concentration of 3%. After manufacturing, it is poured into sterilized tubes and placed in a box with 5 applicators. Each applicator contains 5 grams of cream, which the patient is instructed to use every night for 5 nights. Explanations regarding not using other drugs and antibiotics and not using vaginal douche and other vaginal drugs during the treatment period will be given to the intervention group.

Category

Treatment - Drugs

2

Description

Control group: The control group will be clotrimazole vaginal cream. Tubes of Clotrimazole Vaginal Cream and Calendula Gel will match in terms of color, smell, size and shape. Each applicator contains 5 grams of cream, which the patient is instructed to use every night for 5 nights. Explanations regarding not using other drugs and antibiotics and not using vaginal douche and other vaginal drugs during the treatment period will be given to the control group.

Category

Placebo

Recruitment centers

1

Recruitment center

Name of recruitment center

15 Golestan St, Shahid Mofteh Clinic, Yasuj

Full name of responsible person

Leila Bozorgian

Street address

Shahid Jalil St., Educational Campus, Medicinal Plants Research Center

City

Yasuj

Province

Kohgiluyeh-va-Boyerahmad

Postal code

7591994799

Phone

+98 74 3323 0240

Email

Sponsors / Funding sources

1

Sponsor

Name of organization / entity

Yasouj University of Medical Sciences

Full name of responsible person

Dr. Sayed Amin Hosseini motlagh

Street address

Shahid Jalil Street, Educational Campus

City

Yasuj

Province

Kohgiluyeh-va-Boyerahmad

Postal code

7591994799

Phone

+98 74 3323 0240

Email

liela.bozorgian1@gmail.com

Grant name**Grant code / Reference number****Is the source of funding the same sponsor organization/entity?**

Yes

Title of funding source

Yasouj University of Medical Sciences

Proportion provided by this source

100

Public or private sector

Public

Domestic or foreign origin

Domestic

Category of foreign source of funding

empty

Country of origin**Type of organization providing the funding**

Academic

2

Sponsor

Name of organization / entity

Vice President of Research and Technology of Yasouj
University of Medical Sciences

Full name of responsible person

Dr. Sayed Amin Hosseini motlagh

Street address

Yasouj, Shahid Motahari St., Yasouj University of
Medical Sciences, Deputy of research and technology

City

Yasuj

Province

Kohgiluyeh-va-Boyerahmad

Postal code

7591994799

Phone

+98 74 3344 3931

Fax**Email**

sisacohortpersian@gmail.com

Web page address

http://cohort.yums.ac.ir/

Grant name**Grant code / Reference number****Is the source of funding the same sponsor organization/entity?**

Yes

Title of funding source

Vice President of Research and Technology of Yasouj
University of Medical Sciences

Proportion provided by this source

100

Public or private sector

Public

Domestic or foreign origin

Domestic

Category of foreign source of funding

empty

Country of origin**Type of organization providing the funding**

Academic

Person responsible for general inquiries

Contact

Name of organization / entity

Yasouj University of Medical Sciences

Full name of responsible person

Leila Bozorgian

Position

Midwifery Instructor

Latest degree

Master

Other areas of specialty/work

Midwifery

Street address

Shahid Jalil Street, Educational Campus

City

Yasuj

Province

Kohgiluyeh-va-Boyerahmad

Postal code

7591994799

Phone

+98 74 3323 0240

Email

liela.bozorgian1@gmail.com

Person responsible for scientific inquiries

Contact

Name of organization / entity

Yasouj University of Medical Sciences

Full name of responsible person

Leila Bozorgian

Position

Midwifery Instructor

Latest degree

Master
Other areas of specialty/work
Midwifery
Street address
Shahid Jalil Street, Educational Campus
City
Yasuj
Province
Kohgiluyeh-va-Boyrahmad
Postal code
7591994799
Phone
+98 74 3323 0240
Email
liela.bozorgian1@gmail.com

Person responsible for updating data

Contact

Name of organization / entity
Yasouj University of Medical Sciences
Full name of responsible person
Leila Bozorgian
Position
Midwifery Instructor
Latest degree
Master
Other areas of specialty/work
Midwifery
Street address
Shahid Jalil Street, Educational Campus
City

Yasuj
Province
Kohgiluyeh-va-Boyrahmad
Postal code
7591994799
Phone
+98 74 3323 0240
Email
liela.bozorgian1@gmail.com

Sharing plan

Deidentified Individual Participant Data Set (IPD)

Undecided - It is not yet known if there will be a plan to make this available

Study Protocol

Undecided - It is not yet known if there will be a plan to make this available

Statistical Analysis Plan

Undecided - It is not yet known if there will be a plan to make this available

Informed Consent Form

Undecided - It is not yet known if there will be a plan to make this available

Clinical Study Report

Undecided - It is not yet known if there will be a plan to make this available

Analytic Code

Undecided - It is not yet known if there will be a plan to make this available

Data Dictionary

Undecided - It is not yet known if there will be a plan to make this available